KDM1A and leukemia: Recent studies have suggested combinatorial therapies, i.e., approaches involving the inhibition of DOT1L (an H3K79 methyltransferase) and the bromo-domain protein BRD4, together with the inhibition of KDM1A, to treat MLL-rearranged leukemia [166].